0.060
0.01 (16.28%)
| 前收盘价格 | 0.052 |
| 收盘价格 | 0.052 |
| 成交量 | 92,282 |
| 平均成交量 (3个月) | 322,306 |
| 市值 | 2,022,527 |
| 市盈率 (P/E TTM) | 0.000 |
| 预期市盈率 (P/E Forward) | 0.370 |
| 价格/销量 (P/S) | 660.53 |
| 股市价格/股市净资产 (P/B) | 0.610 |
| 52周波幅 | |
| 利润日期 | 18 Aug 2025 - 22 Aug 2025 |
| 稀释每股收益 (EPS TTM) | -6,321.50 |
| 总债务/股东权益 (D/E MRQ) | 15.34% |
| 流动比率 (MRQ) | 0.250 |
| 营业现金流 (OCF TTM) | -14.86 M |
| 杠杆自由现金流 (LFCF TTM) | -13.41 M |
| 资产报酬率 (ROA TTM) | -53.20% |
| 股东权益报酬率 (ROE TTM) | -124.86% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Windtree Therapeutics, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.50 |
|
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 0.01% |
| 机构持股比例 | 1.39% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合